ArticleCell2026
Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections.
Abstract read
In one paragraph
Article in Cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Autoantibodies neutralizing type I interferons underlie a third of cases of Chikungunya virus encephalitis or myelitis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Variant-specific spike conformational dynamics shape memory B cell selection during recall.bioRxiv : the preprint server for biology · 2026Article
- Toward a monogenic architecture of human infections: From 1996 to 2026.Journal of human immunity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
60 authors.
Morgane FournierInstitut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Université Paris Cité, Paris, France.
Matthias VanderkerkenInstitut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Université Paris Cité, Paris, France.
Karim DorghamSorbonne Université, INSERM, CIMI, Département d'Immunologie, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
Paul BastardSt Giles Laboratory of Human Genetics of Infectious Diseases, INSERM U1163, Necker Hospital for Sick Children, Paris, France; Imagine Institute, Université Paris Cité, Paris, France; St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA; Department of Pediatric Immuno-Hematology and Rheumatology, CHU Necker-Enfants Malades, AP-HP, Paris, France.
Olivia AhouziInstitut Pasteur, Université Paris Cité, CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.
Stephane DuquerroyInstitut Pasteur, Université Paris Cité, CNRS UMR 3569, Unité de Virologie Structurale, Paris, France; Université Paris-Saclay, Faculté des Sciences, Orsay, France.
Ngoc Khanh NguyenSorbonne Université, INSERM, CIMI, Département d'Immunologie, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
Manon BroutinInstitut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Université Paris Cité, Paris, France.
Manon CharletInstitut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Université Paris Cité, Paris, France.
Alexis VandenbergheInstitut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Université Paris Cité, Paris, France; Service de Médecine Interne, CHU Henri-Mondor, AP-HP, UPEC, Créteil, France.
Paolo Van EndertInstitut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Université Paris Cité, Paris, France.
Lucy BizienSt Giles Laboratory of Human Genetics of Infectious Diseases, INSERM U1163, Necker Hospital for Sick Children, Paris, France; Imagine Institute, Université Paris Cité, Paris, France.
Omaira Da Mata-JardinSorbonne Université, INSERM, CIMI, Département d'Immunologie, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
Andrés Ferriño-IriarteInstitut Pasteur, Université Paris Cité, CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.
Ahmed HaouzInstitut Pasteur, Université Paris Cité, CNRS UMR 3528, Crystallography Facility-C2RT, Paris, France.
Thibaut BelmondoDépartement Immunologie-Hématologie, CHU Henri-Mondor, AP-HP, UPEC, Créteil, France.
Sophie HüeDépartement Immunologie-Hématologie, CHU Henri-Mondor, AP-HP, UPEC, Créteil, France.
Alessandro BorghesiHost-Pathogen Interaction Group, San Matteo Research Hospital, Pavia, Italy; Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland; Neonatal and Pediatric Intensive Care Unit, Mother, Child and Adolescent Department, Geneva University Hospitals, Geneva, Switzerland.
Carlos Rodríguez-GallegoDepartment of Immunology, University Hospital Gran Canaria Dr. Negrín, Canarian Health System, Las Palmas de Gran Canaria, Spain; Department of Medical and Surgical Sciences, School of Medicine, University of Las Palmas de Gran Canaria, and Instituto de Investigación Sanitaria de Canarias, Tenerife, Spain; Department of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
Donald C VinhDepartment of Medicine, Division of Infectious Diseases, McGill University Health Centre, Montréal, and Infectious Disease Susceptibility Program, Research Institute-McGill University Health Centre, Montréal, QC, Canada.
Evangelos AndreakosLaboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Filomeen HaerynckDepartment of Pediatric Immunology and Pulmonology, CPIG, Jeffrey Modell Diagnosis and Research Centre, Ghent University Hospital, Ghent, Belgium; Department of Pediatrics and Internal Medicine, PID research laboratory, Ghent University, Ghent, Belgium.
Rabih HalwaniResearch Institute for Medical and Health Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates; Immunology Research Lab, College of Medicine, King Saud University, Riyadh, Saudi Arabia; Health and Wellbeing, NEOM, Tabuk, Saudi Arabia; Prince Fahad Bin Sultan Chair for Biomedical Research, University of Tabuk, Tabuk, Saudi Arabia; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Qiang Pan-HammarströmDivision of Immunology, Department of Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
Niklas K BjörkströmCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
Benedikt StrunzCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
Trine H MogensenDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; Department of Biomedicine, Aarhus University, Aarhus, Denmark.
COVID Human Genetic Effort
Antonio PirallaMicrobiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Stefania VarchettaInfectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Laboratory of Clinical Immunology, Division of Molecular Medicine, Rare Diseases and Advanced Therapy, Department of Experimental and Clinical Research, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Jorge FreixinetDepartment of Medical and Surgical Sciences, School of Medicine, University of Las Palmas de Gran Canaria, and Instituto de Investigación Sanitaria de Canarias, Tenerife, Spain; Department of Thoracic Surgery, University Hospital of Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain; IUIBS, Las Palmas de Gran Canaria, Spain.
Lucie RousselDepartment of Medicine, Division of Infectious Diseases, McGill University Health Centre, Montréal, and Infectious Disease Susceptibility Program, Research Institute-McGill University Health Centre, Montréal, QC, Canada.
Sophie Trouillet AssantHospices Civils de Lyon, Lyon Sud Hospital, International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France.
Bénédicte NevenDepartment of Pediatric Immuno-Hematology and Rheumatology, CHU Necker-Enfants Malades, AP-HP, Paris, France.
Romain LevyDepartment of Pediatric Immuno-Hematology and Rheumatology, CHU Necker-Enfants Malades, AP-HP, Paris, France.
Tom le VoyerSt Giles Laboratory of Human Genetics of Infectious Diseases, INSERM U1163, Necker Hospital for Sick Children, Paris, France; Imagine Institute, Université Paris Cité, Paris, France; St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
Ottavia M DelmonteLaboratory of Clinical Immunology and Microbiology, Division of Intramural Research, NIAID, NIH, Bethesda, MD, USA.
Cliona O'FarrellySchool of Medicine, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland.
Jacques RivièrePediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Blanca Amador BorreroInternal Medicine Department, Hôpital Lariboisière, AP-HP, Université Paris Cité, Paris, France.
Amélie ServettazService de médecine interne, faculté de médecine de Reims, CHU de Reims, EA 7509, Université Reims Champagne Ardenne, Reims, France.
Roger D KouyosDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, and Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Daniel E KaufmannDivision of Infectious Diseases, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Etienne CrickxService de Médecine Interne, CHU Henri-Mondor, AP-HP, UPEC, Créteil, France.
Marc MichelService de Médecine Interne, CHU Henri-Mondor, AP-HP, UPEC, Créteil, France.
Anne PuelSt Giles Laboratory of Human Genetics of Infectious Diseases, INSERM U1163, Necker Hospital for Sick Children, Paris, France; Imagine Institute, Université Paris Cité, Paris, France.
Laurent AbelSt Giles Laboratory of Human Genetics of Infectious Diseases, INSERM U1163, Necker Hospital for Sick Children, Paris, France; Imagine Institute, Université Paris Cité, Paris, France.
Charles-Edouard LuytMédecine Intensive Réanimation, Institut de Cardiologie, AP-HP, Pitié-Salpêtrière, Sorbonne-Université, INSERM, UMRS_1166-ICAN, Paris, France.
Alexis MathianAP-HP, Pitié-Salpêtrière, Service de Médecine Interne 2, Institut E3M, INSERM, Paris, France.
Kai KisandMolecular Pathology, Department of Biomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Darragh DuffyTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.
Lluis Quintana-MurciHuman Evolutionary Genetics Unit, Institut Pasteur, Université Paris Cité, Paris, France; Chair Human Genomics and Evolution, Collège de France, Paris, France.
Zahir AmouraSorbonne Université, INSERM, CIMI, Département d'Immunologie, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
Benjamin G HaleInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.
Jean-Claude WeillInstitut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Université Paris Cité, Paris, France.
Jean-Laurent CasanovaSt Giles Laboratory of Human Genetics of Infectious Diseases, INSERM U1163, Necker Hospital for Sick Children, Paris, France; Imagine Institute, Université Paris Cité, Paris, France; St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA; Howard Hughes Medical Institute, New York, NY, USA; Department of Pediatrics, Necker Hospital for Sick Children, Paris, France. Electronic address: casanova@rockefeller.edu.
Felix A ReyInstitut Pasteur, Université Paris Cité, CNRS UMR 3569, Unité de Virologie Structurale, Paris, France. Electronic address: felix.rey@pasteur.fr.
Guy GorochovSorbonne Université, INSERM, CIMI, Département d'Immunologie, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France. Electronic address: guy.gorochov@inserm.fr.
Pascal ChappertInstitut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Université Paris Cité, Paris, France; INSERM U955, équipe 2, IMRB, UPEC, Créteil, France. Electronic address: pascal.chappert@inserm.fr.
Matthieu MahévasInstitut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Université Paris Cité, Paris, France; Service de Médecine Interne, CHU Henri-Mondor, AP-HP, UPEC, Créteil, France; INSERM U955, équipe 2, IMRB, UPEC, Créteil, France. Electronic address: matthieu.mahevas@aphp.fr.
Funding
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MMonogenic basis of resistance to SARS-CoV2 and predisposition to severe COVID-19R01AI088364 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Jean-Laurent Casanova, Shen-Ying Zhang · 2010 to 2026
$8.7MInborn errors of immunity in patients with life-threatening COVID-19R01AI163029 · NIAID · ROCKEFELLER UNIVERSITY · PI CASANOVA, JEAN-LAURENT, ZHANG, QIAN · 2021 to 2025
$3.7MSingle gene inborn errors of immunity underlying SARS-CoV-2-related multisystem inflammatory syndrome in children: a new approach to tackle a seemingly old puzzleR21AI160576 · NIAID · ROCKEFELLER UNIVERSITY · PI ZHANG, SHEN-YING · 2022 to 2023
$466kHoward Hughes Medical InstituteNCATS NIH HHS UL1 TR001866NIAID NIH HHS R01 AI088364NIAID NIH HHS R01 AI163029NIAID NIH HHS R21 AI160576Wellcome Trust
Abstract
Autoantibodies neutralizing type-I interferons (AAN-I-IFNs) emerge as global, common, and strong determinants of a growing number of severe viral diseases. We report that AAN-I-IFNs
Indexed as
Antibodies, NeutralizingB-LymphocytesCOVID-19Interferon Type IAutoantibodiesCrystallography, X-RayEpitopes, B-LymphocyteHumansSARS-CoV-2Antibodies, NeutralizingAutoantibodiesEpitopes, B-LymphocyteInterferon Type Iaffinity maturationantibodiesautoimmunityB cellsCOVID-19memory B cellsSars-CoV-2severe viral infectionstype-I interferon
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.